

APPENDICES

LEGISLATIVE CHRONOLOGY

NOV. 1, 1948

The National Microbiological Institute was established under authority of section 202 of the Public Health Service Act, as implemented by General Circular No. 55, Organization Order No. 20, dated October 8, 1948.

DEC. 29, 1955

NIAID was established (replacing the National Microbiological Institute) under authority of the Omnibus Medical Research Act (Public Law 81-692, 64 Stat. L. 443), as implemented by a Public Health Service Briefing Memorandum of November 4, 1955, from the Surgeon General to the Secretary of Health, Education, and Welfare.

NOV. 4, 1988

NIAID was provided with additional authorities for AIDS research under Title II of the Health Omnibus Programs Extension of 1988 (HOPE legislation) (Public Law 100-07), the first major law to address AIDS research, information, education, and prevention.

AUG. 14, 1991

The Public Health Service Act was amended by Public Law 102-96, the Terry Beirn Community-Based AIDS Research Initiative Act of 1991, which reauthorized NIAID's Community Programs for Clinical Research on AIDS (CPCRA). CPCRA was renamed in honor of Mr. Beirn (an AIDS activist and congressional staffer who died in 1991) and was reauthorized for an additional 5 years.

JUNE 10, 1993

The Public Health Service Act was amended by Public Law 103-43, the National Institutes of Health Revitalization Act of 1993. This comprehensive legislation required NIAID to include research on tropical diseases in its mission statement and directs the Secretary, U.S. Department of Health and Human Services, to ensure that individuals with expertise in chronic fatigue syndrome or neuromuscular diseases are appointed to appropriate NIH advisory committees.

DEC. 14, 1993

The Preventive Health Amendments of 1993 were passed, which included provisions requiring the Director, NIAID, to conduct or support research and research training regarding the cause, early detection, prevention, and treatment of tuberculosis. (The Institute already had authority to conduct such research under its authorities in Title IV, Public Health Service Act.)

NOV. 29, 1999

The fiscal year 2000 Appropriations Act (Public Law 106-113) established the NIH Challenge Grants program to promote joint ventures between the NIH and the biotechnology, pharmaceutical, and medical device industries. A one-time funding level of \$20 million was provided within the Public Health and Social Services Emergency Fund.

OCT. 17, 2000

The Children's Health Act (Public Law 106-310) required the Directors of NIAID and the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand and intensify the activities of their Institutes with respect to research and related activities concerning juvenile arthritis and related conditions.

NOV. 13, 2000

The Public Health Improvement Act (Public Law 106-505) authorized the NIAID Director to establish a program of clinical research and training awards for sexually transmitted infections.

July 21, 2004

The Project Bioshield Act (Public Law 108-276) authorized the Director of NIH to employ expedited peer review procedures for grants, contracts, and cooperative agreements addressing qualified countermeasures research. In addition, the Act authorized the Director of NIAID to award grants or contracts to public and nonprofit private entities to expand, remodel, renovate, or alter existing research facilities or construct new facilities.

Previous Directors

Victor H. Haas, M.D., 1948–1957

Justin M. Andrews, Sc.D., 1957–1964

Dorland J. Davis, M.D., D.P.H., 1964–1975

Richard M. Krause, M.D., 1975–1984

TECHNOLOGY TRANSFER

Technology transfer in Federal laboratories facilitates the dissemination of new technologies and research materials developed by Government scientists. This technology transfer fuels further innovation and commercialization by the extramural research and development community, ultimately resulting in an improvement in the public health and an increase in the competitiveness of U.S. industry. Federal legislation mandates and defines the Government’s technology transfer activities. The key pieces of legislation are the Federal Technology Transfer Act of 1986 and the National Technology Transfer and Advancement Act of 1995.

The NIAID Office of Technology Development (OTD) accomplishes technology transfer by facilitating the transfer of significant research advances and resources to the broader scientific community and the development of collaborative relationships between NIAID scientists, industry, and academia. NIAID uses various mechanisms to accomplish these ends, including Material Transfer Agreements (MTAs), Cooperative Research and Development Agreements (CRADAs), Materials-CRADAs (M-CRADAs), Confidential Disclosure Agreements (CDAs), Clinical Trial Agreements (CTAs), Drug Screening Agreements (DSAs), Collaboration Agreements (CAs), and, through the NIH Office of Technology Transfer (OTT), the patenting of inventions and the negotiation of various license agreements.

NIAID scientists report inventions to OTD by submitting Employee Invention Reports (EIRs). The EIRs are reviewed by OTD and, with the assistance of the NIAID Technology Evaluation Advisory Committee (TEAC), are evaluated for the purpose of filing domestic and foreign patent applications. In fiscal year (FY) 2004, TEAC reviewed 41 intramural EIRs and recommended that patent applications be filed on 26 of them.

NIAID currently has 386 active U.S. patent properties, including 209 issued patents and 177 pending patent applications.

NIAID had a total of 226 active license agreements in FY 2004 for both patented inventions and biological materials. These licenses generated about \$11 million in royalty income, which was first used to pay NIAID inventors their share according to Federal law and NIH policy. The Institute also distributed royalty income to intramural laboratories to support research projects and equipment acquisition that otherwise would not have been accomplished with appropriated funds. The remaining royalties were used to pay OTD’s entire operating budget, including patent prosecution fees, OTD staff salaries, associated office expenses, and overhead charged by OTT.

In FY 2004, a total of 128 MTAs, 9 CTAs, 53 CDAs, 6 CRADAs, 12 M-CRADAs, 5 CAs, and 15 other agreements were executed and negotiated by OTD. NIAID extramural divisions referred technology transfer issues to OTD on 9 contracts, and OTD NIAID scientists performed research under 32 CRADAs and 38 M-CRADAs in FY 2004. The following table provides a history of NIAID’s patent, license, and CRADA activities.

NIAID Technology Transfer Activities

Fiscal Year	Pending Patents	Issued Patents	Licenses In Effect	Active CRADAs
1992	77	48	65	21
1994	85	65	84	29
1995	96	71	101	31
1996	95	84	120	42
1997	128	91	131	71
1998	154	83	155	95
1999	169	94	195	74
2000	229	100	196	86
2001	194	125	190	93
2002	147	139	197	85
2003	174	168	245	71
2004	177	209	226	70

Technology Transfer Highlights

In FY 2004, OTD negotiated or facilitated the following public-private partnerships:

- **Development and selection of research-grade plasmid DNA vectors encoding West Nile virus proteins and formulations for potential use as prophylactic vaccines in human and veterinary applications (Vical)**
Investigators at the Vaccine Research Center (VRC), NIAID, and Vical, Incorporated will collaborate in the development and evaluation of West Nile Virus (WNV) DNA vaccine candidates. Recently, WNV DNA vaccines have shown promising protection in animal studies. The VRC and Vical will evaluate materials that might enhance or improve the immune response to WNV and select the best constructs and formulations of WNV DNA vaccine candidates appropriate for clinical development.
- **Evaluation of herpes simplex virus vectors encoding HIV-1 proteins (BioVex).** Herpes simplex virus (HSV) vectors are being investigated as a gene delivery system for gene therapy and vaccination. Recombinant HSV vectors offer a promising strategy for development of a candidate HIV-1 vaccine that could be effective in humans. Investigators at the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institute of Health, and BioVex, Ltd. will collaborate to evaluate and develop HSV vectors expressing VRC's modified HIV-1 genes. The collaboration will evaluate such HSV vectors for potential application as an HIV preventive or therapeutic vaccine. The VRC will provide BioVex with several modified HIV-1 genes, and BioVex will construct and produce recombinant HSV vectors that express VRC's HIV-1 genes utilizing the BioVex HSV system. The overall goal is to provide the VRC with advanced vector technologies suitable for rapid advancement toward clinical trial.
- ***In vitro* and *in vivo* evaluation of novel compounds with antitubercular activity (Anacor Pharmaceuticals).** Anacor Pharmaceuticals and the Tuberculosis Research Section of the Laboratory of Host Defenses, NIAID, NIH, are entering into a collaborative research and development agreement to screen promising candidate molecules for activity against *Mycobacterium tuberculosis*. These molecules have been shown to have a unique mechanism of action that targets problematic Gram-positive pathogens and members of this series. By providing selectivity for the treatment of tuberculosis these molecules may have utility in the chemotherapy of this important disease.
- **Development of prophylactic and therapeutic monoclonal antibodies to vaccinia/smallpox, SARS, and anthrax (MacroGenics).** Under this Cooperative Research and Development Agreement, investigators in the Laboratory of Infectious Diseases, the Laboratory of Viral Diseases, and the Bacterial Toxins and Therapeutics Section Division of Intramural Research at NIAID and MacroGenics, Inc., will attempt to isolate and characterize human and human-like neutralizing monoclonal antibodies to vaccinia virus, the SARS virus, and anthrax.
- **Identification of novel antitubercular agents through high-throughput screening (Exelixis).** The Tuberculosis Research Section of NIAID and Exelixis, Inc., are collaborating under this CRADA to screen compound libraries for potential new compounds active against *M. tuberculosis*, which can then be put forward for the treatment of tuberculosis.
- **Chlamydial antigen discovery (Chiron).** A cooperative approach will be used to

identify novel chlamydial antigens important to chlamydial vaccine development. The project involves the combination of *in vitro* models of cytokine mediated chlamydial persistent infection, isolation of HLA class I and II processed peptides from infected epithelial cells, elution of peptides from HLA

molecules, and identification of peptides and native proteins by high-throughput mass spectrometry. The identified peptides might represent unique hereto-undiscovered antigens important to protective cellular immune responses and future anti-chlamydial therapeutic strategies.

New CRADAs

During FY 2004, NIAID scientists entered into the following six new CRADAs:

Collaborator	Investigator	Title
Anacor Pharmaceuticals, Inc.	Clifton E. Barry III, Ph.D. Laboratory of Immunogenetics	<i>In Vitro</i> and <i>In Vivo</i> screening of Novel Antitubercular Agents.
BioVex, Ltd.	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Evaluation of HSV Vectors Encoding HIV-1 Proteins.
Chiron Corp.	Harlan D. Caldwell, Ph.D., Laboratory of Intracellular Parasites	Chlamydia Antigen Discovery.
Exelixis, Inc.	Clifton E. Barry III, Ph.D. Laboratory of Immunogenetics	New Lead Discovery for the Identification of Novel Antitubercular Agents.
MacroGenics, Inc.	Robert H. Purcell, M.D. Laboratory of Infectious Diseases	Development of Prophylactic and Therapeutic Monoclonal Antibodies to Vaccinia/Smallpox, SARS, and Anthrax.
Vical, Inc.	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Development And Selection Of Research-Grade Plasmid DNA Vectors Encoding West Nile Virus (WNV) Proteins And Formulations For Potential Use As Prophylactic Vaccines In Human And Veterinary Applications.

Ongoing CRADAs

In addition to the new CRADAs, research was done under the following ongoing CRADAs:

Collaborator	Investigator	Title
Achillion Pharmaceuticals NCI	John Inman, Ph.D. Laboratory of Immunology	Development of Optimized Inhibitors of Protein Zinc Finger Domains
Chiron	H. Clifford Lane, M.D. Laboratory of Immunoregulation	Research and Development of IL-2 as a Treatment for HIV Infection
Crucell	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Development of an Improved Recombinant Adenovirus Vector for Vaccination Against the Ebola Virus
Genetics Institute	Ethan Shevach, M.D. Laboratory of Immunology	Analysis Of Gene Expression In Immunoregulatory T Cells That Co-Express The CD4 And CD25 Surface Markers

Collaborator	Investigator	Title
Genetics Institute	Thomas Wynn, Ph.D. Laboratory of Parasitic Disease	Development Of IL-13 Antagonism As A Treatment For Fibrosis In Schistosomiasis
Genetics Institute	Warren Strober, M.D. Peter Mannon, M.D. Ivan Fuss, M.D. Laboratory of Clinical Investigation	A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study Of Two Parallel Dose Levels Of Subcutaneously Administered Human Monoclonal Antibody To Interleukin-12 (J695) In Patients With Active Crohn's Diseases
GenVec	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Evaluation of Adenoviral Vectors Encoding HIV-1 Proteins
GenVec	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Evaluation of Adenoviral Vectors Encoding Proteins Associated with SARS
Glaxo Research & Development	Clifton E. Barry III, Ph.D. Laboratory of Immunogenetics	Development of New Drugs for the Treatment of Tuberculosis
GlaxoSmithKline	Holli Hamilton, M.D., M.P.H. Barbara Savarese, R.N. Division of Microbiology and Infectious Diseases	A Double-Blind, Randomized, Controlled Phase III Study To Assess The Prophylactic Efficacy Of Rgd/Alum/MPL Vaccine In The Prevention Of Genital Herpes Disease In Young Sexually Active Women (DMID#01-643)
IAVI	Richard T. Wyatt, Ph.D. Vaccine Research Center	Rational Design of HIV Envelope Glycoprotein Variants for Structural and Immunological Analysis Using X-Ray Crystallography To Elicit Broadly Neutralizing HIV-1 Antibodies.
Ichor Medical Systems	Phillip Gomez III, Ph.D., M.B.A. Vaccine Research Center	Evaluation Of Electroporation-Mediated Delivery Of An HIV DNA Vaccine
Innogenetics	Robert H. Purcell, M.D. Laboratory of Infectious Diseases	Analysis of the Immune Response to Hepatitis C Virus
Invitrogen	Thomas Kindt, Ph.D. Michael Wilson, Ph.D. Research Technologies Branch, Division of Intramural Research	Oligonucleotide Control Sets for Microarray Applications
Maxygen	Louis Miller, M.D. Carole Long, Ph.D. Allan Saul, Ph.D. Laboratory of Parasitic Disease	Novel, Polyspecific Malaria Vaccine Development Based on PfEMP1 Using Molecular Breeding™ Directed Molecular Evolution Technologies
MedImmune Vaccines (formerly Aviron)	George Curlin, M.D. Division of Microbiology and Infectious Diseases	Development of a Live, Attenuated Cold-Adapted Influenza Vaccine
Merck	Gary Nabel, M.D., Ph.D. Vaccine Research Center	Development of an Adenoviral-Based HIV Vaccine
Merck	Stephen Straus, M.D. Laboratory of Clinical Investigation	A Double-Blind, Placebo-Controlled Study Of The Efficacy Of Live, Attenuated Oka/Merck Varicella Zoster Vaccine In Reducing The Incidence And/Or Severity Of Shingles In Adults

Collaborator	Investigator	Title
Merial	José Ribeiro M.D., Ph.D. Laboratory of Parasitic Disease	Evaluation Of DNA Vaccines Encoding Sand Fly Salivary Proteins As Candidates To Control <i>Leishmania Infantum</i> Infection In Dog
Nexell Therapeutics	Harry L. Malech, M.D. Mitchell Horwitz, M.D. Laboratory of Host Defenses	Study of Low Intensity Preparative Regimen Followed By HLA-Matched Transplantation for Chronic Disease
Novartis	Marshall Plaut, M.D. Division of Allergy, Immunology, and Transplantation	A Double-Blind, Placebo Controlled Study Of The Efficiency of E25 Anti-Ige Reducing Asthma Symptoms In Inner City Children
Novavax	Louis Miller, M.D. Laboratory of Parasitic Disease	Merozoite Surface Protein 1 Expressed in Insect Cells: Process Development, Preclinical and Initial Clinical Evaluation
Osel	Edward Berger, Ph.D. Laboratory of Viral Diseases	SCD4-17b Expressed By/On <i>Lactobacillus</i> As An Anti-HIV Topical Microbicide
Panacos	Eric Freed, Ph.D. Laboratory of Molecular Microbiology	A Study of the Mechanism of Action of the Anti-HIV Compound, PA-457
Quantum Dot	Mario Roederer, Ph.D. Vaccine Research Center	Use of Quantum Dots for Improved Cellular Classification in Flow Cytometry
Wyeth-Lederle Vaccines	Pamela McInnes, Ph.D. Division of Microbiology and Infectious Diseases	Preventing Childhood Mortality—An Efficacy Trial of a Pneumococcal Conjugate Vaccine in Upper and Central River Divisions, The Gambia

NIH EXTRAMURAL FUNDING MECHANISMS USED BY NIAID

Fellowship Programs

- F31** Predoctoral Individual National Research Service Award (NRSA)—provides predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.).
- F32** Postdoctoral Individual NRSA—provides postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
- F33** NRSA for Senior Fellows—provides opportunities for experienced scientists to make major changes in the direction of their research careers, to broaden their scientific background, or to acquire new research capabilities.
- F35** Intramural NRSA Individual Postdoctoral Program—supports a postdoctoral trainee in the NIH intramural program.

Research Career Programs

- K02** Independent Scientist Award—provides support for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers.
- K08** Clinical Investigator Award—provides the opportunity for promising medical scientists (with demonstrated aptitude to develop into independent investigators) or faculty members who will pursue research aspects of categorical areas applicable to the awarding unit, and aids in filling the important academic faculty

gap in these shortage areas within health professional institutions of the country.

- K22** Career Transition Award—provides support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment of the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
- K23** Mentored Patient-Oriented Research Career Development Award—provides support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
- K24** Midcareer Investigator Award in Patient-Oriented Research—provides support for experienced clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators.
- K25** Mentored Quantitative Research Career Development Award—supports junior faculty-level investigators with quantitative scientific and engineering backgrounds outside of biology or medicine who have the potential to integrate their expertise with biomedicine and to develop into productive investigators with a period of mentored study and research.

K30 Clinical Research Curriculum Award (CRCA)—awarded to institutions to stimulate the inclusion of high-quality, multidisciplinary didactic training as part of the career development of clinical investigators. This award supports the development of new didactic programs in clinical research at institutions that do not offer such programs or in institutions with existing programs in clinical research. In the latter, it supports the expansion of programs or improvement in the quality of instruction.

Research and Development-Related Contracts

N01 Research and Development (R&D) Contract—develops or applies new knowledge or tests, screens, or evaluates a product, material, device, or component for use by the scientific community.

Research Program Projects and Centers

P01 Research Program Project—provides a qualified institution, on behalf of a principal investigator, with the support of a broad-based, multidisciplinary, often long-term research program with a particular major objective or theme. A program project involves the organized efforts of groups of investigators who conduct research projects related to the overall program objective. The grant can provide support for the projects and for certain shared resources necessary for the total research effort. Each project supported under a program project grant is expected to contribute to the overall program objective.

P30 Center Core Grant—supports shared resources and facilities for categorical research by a number of investigators

from different disciplines who provide a multidisciplinary approach to a joint research effort or from the same discipline who focus on a common research problem. Although funded independently of the center's component projects or program projects, the core grant relates integratively to them. By providing more accessible resources, this support is expected to ensure greater productivity than that obtained from the separate projects and program projects.

P50 Specialized Center—supports any part of the full range of R&D, from basic to clinical, and may involve ancillary supportive activities, such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These grants differ from program project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

Research Project Grants and Grants Related to Research Projects

R01 Research Project Grant (traditional)—provides support to an institution (domestic or foreign) on behalf of a principal investigator for a discrete project related to the investigator's interests and competence. Most of the research that the NIH supports is maintained through this funding mechanism. Although rare, such a grant may be awarded directly to an individual.

- R03** Small Grant—provides research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are nonrenewable.
- R09** Scientific Evaluation—provides the chairman of an initial review group funds for operation of the initial review group.
- R13** Conference Grant—provides funding for conferences to coordinate, exchange, and disseminate information related to program interests. In general, such awards are modest and limited to participation with other organizations in the support of conferences rather than as a provision of sole support. Among the costs eligible for support are salaries, equipment rental, travel, consultant services, and supplies. Prospective applicants should inquire in advance concerning possible interest on the part of an Institute.
- R15** Academic Research Enhancement Award (AREA)—provides support to scientists at eligible domestic institutions for small-scale, new, or expanded health-related research projects, such as pilot research projects and feasibility studies; development, testing, and refinement of research techniques; secondary analysis of available data sets; and similar discrete research projects that demonstrate research capability. This award is directed toward smaller, less-prominent 4-year public and private colleges and universities that provide undergraduate training for a significant number of U.S. research scientists but have not had an adequate share in the growth of the NIH extramural program.
- R18** Research Demonstration and Dissemination Project—provides support to develop, test, and evaluate health-service activities and to foster the application of existing knowledge for the control of categorical diseases.
- R21** Exploratory/Developmental Grant—used by NIAID for bridge awards. The bridge award provides support for a limited time and amount to investigators to enable them to continue meritorious research and improve the competitiveness of future grant applications.
- R24** Resource-Related Research Project—supports research projects that will enhance the capability of resources to serve biomedical research.
- R25** Education Project—provides support to develop or implement a program in education, information, training, technical assistance, coordination, or evaluation.
- R33** Exploratory and Developmental Grants, Phase II—provide a second phase of support for innovative, exploratory, and developmental research begun as an R21 award. Only R21 awardees are eligible to apply for R33 support. Applications are accepted only in response to RFAs and PAs that specify the R33 mechanism.
- R37** Method to Extend Research in Time (MERIT) Award—provides long-term, stable support to investigators who are likely to continue to perform in an outstanding manner and spares them the administrative burdens associated with preparing and submitting research grant applications. An initial 5-year award is accompanied by an opportunity for a 3- to 5-year extension, based on an expedited review of the accomplishments during the initial award period. Investigators may not apply for a MERIT

award. NIH staff and advisors base their selection of MERIT award recipients on competing R01 applications, prepared and submitted in accordance with NIH procedures. MERIT awards are awarded to a limited number of selected investigators who have demonstrated superior competence and outstanding productivity during previous research endeavors.

Small Business Funding Opportunities

- R41** Small Business Technology Transfer Research (STTR) Grant, Phase I—supports cooperative R&D projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas that have potential for commercialization. Awards are made to small business concerns only.
- R42** STTR Grant, Phase II—supports cooperative R&D projects between small business concerns and research institutions, limited in time and amount, to establish the technical merit and feasibility of ideas that have potential for commercialization. Awards are made to small business concerns only.
- R43** Small Business Innovation Research (SBIR) Grant, Phase I—enables small businesses to contribute to the R&D mission of the NIH. Phase I grants support projects, limited in time and amount, to establish the technical merit and feasibility of ideas that ultimately may lead to commercial products or services. The research must be conducted in the United States.
- R44** SBIR Grant, Phase II—enables small businesses to contribute to the R&D mission of the NIH. Phase II grants

support indepth development of ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services. The research must be conducted in the United States.

Research Training Programs

- T32** Institutional NRSA—enables institutions to grant NRSA for predoctoral and postdoctoral research training in specified shortage areas to individuals selected by the institutions.
- T35** NRSA Short-Term Research Training—provides individuals with research training during off-quarters or summer periods to encourage research careers or research in areas of national need.

Cooperative Agreements

- U01** Research Project (Cooperative Agreement)—provides an assistance relationship between the NIH and a recipient, but with substantial programmatic involvement by the NIH. The NIH assists, supports, or stimulates the recipients and is involved substantially with recipients in conducting projects similar in program content to those for grants, with the NIH playing a “partner” role in the effort.
- U19** Research Program (Cooperative Agreement)—supports a research program of multiple projects directed toward a specific major objective, basic theme, or program goal that requires a broad-based, multidisciplinary, and often long-term approach.
- U24** Resource-Related Research Projects/Cooperative Agreements—support research projects contributing to

improvement of the capability of resources to serve biomedical research.

U42 Animal (Mammalian and Nonmammalian) Model and Animal and Biomedical Materials Resource Cooperative Agreements (National Center for Research Resources)—develop and support an animal (mammalian and nonmammalian) model or animal or biological materials resources available to all qualified investigators without regard to the scientific disciplines or disease orientations of their research activities or specifically directed to a categorical program. Nonmammalian resources include nonmammalian vertebrates, invertebrates, cell systems, and nonbiological systems.

U54 Specialized Centers Cooperative Agreements—support research and development from basic to clinical, including ancillary supportive activities that create a multidisciplinary focus on a disease or a biomedical problem. Centers also may serve as regional or national resources for special research purposes.

U56 Exploratory Grants Cooperative Agreements—support planning for new programs, expansion or modification of existing resources, and feasibility studies for interdisciplinary programs that may lead to specialized or comprehensive centers.

UC1 NIH Challenge Grants and Partnerships Program, Phase II, Cooperative Agreements (NIAID)—promote joint ventures between the NIH and both domestic and global entities to facilitate rapid biomedical or biotechnology R&D for infectious diseases to benefit public health; projects should have a commercial potential that could not have been attained without matching funds.

Interagency and Intra-Agency Agreements

Y01 NIH Interagency Agreement—provides a written reimbursable agreement by which a component of the NIH provides a source of funds to another Federal organization outside the Department of Health and Human Services (DHHS) to acquire specific products, services, or studies.

Y02 NIH Intra-agency Agreement—provides a written reimbursable agreement by which a component of the NIH provides funds to another NIH component or to another organization within DHHS to acquire specific products, services, or studies.

ACRONYMS

AACTG	Adult AIDS Clinical Trials Group
AADRC	Asthma and Allergic Diseases Research Centers
AAIB	Asthma, Allergy, and Inflammation Branch, DAIT
ACE	Autoimmunity Centers of Excellence
ACERRB	AIDS Clinical and Epidemiology Research Review Branch, DEA
ADAMHA	Alcohol, Drug Abuse, and Mental Health Administration
ADCC	Autoimmune Diseases Coordinating Committee
ADMO	Associate Director for Management and Operations
ADV	adenoviral
AfCS	Alliance for Cellular Signaling
AIDS	acquired immunodeficiency syndrome
AIEDRP	Acute Infection and Early Disease Research Program
AIT	allergen immunotherapy
AMOB	Acquisition Management and Operations Branch, NIAID
APRRB	AIDS Preclinical Research Review Branch, DEA
ARAC	AIDS Research Advisory Committee
AREA	Academic Research Enhancement Award
ART	antiretroviral therapy
ASIR	Richard M. Asofsky Scholars In Research
AVRWG	AIDS Vaccine Research Working Group
BAMBU	Bacteriology and Mycology Biostatistical and Operations Unit
BAMSG	Bacteriology and Mycology Study Group
BIB	Basic Immunology Branch, DAIT
BISC	Bioinformatics Integration Support Contract
BMB	Bacteriology and Mycology Branch, DMID
BRASS	Biomedical Research After School Scholars
BSC	Board of Scientific Counselors
BSE	bovine spongiform encephalopathy
BSL	biosafety level
BSP	Basic Sciences Program, DAIDS
CAB	community advisory board
CAP	community-acquired pneumonia
CASG	Collaborative Antiviral Study Group
CCRB	Complications and Co-Infections Research Branch, DAIDS

CCTPT	Cooperative Clinical Trials in Pediatric Transplantation program
CDA	Confidential Disclosure Agreements
CDC	Centers for Disease Control and Prevention
CEOPP	Community Education and Outreach Partnership Program
CFAR	Centers for AIDS Research
CHAVI	Center for HIV/AIDS Vaccine Immunology
CIB	Clinical Immunology Branch, DAIT
CIPRA	Comprehensive International Program of Research on AIDS
CJD	Creutzfeldt-Jakob disease
CMB	Comparative Medicine Branch, DIR
CMP	Contract Management Program
CMV	cytomegalovirus
CPCRA	Terry Beirn Community Programs for Clinical Research on AIDS
CRADA	Cooperative Research and Development Agreement
CRCA	Clinical Research Curriculum Award
CRMB	Clinical Research Management Branch, DAIDS
CRRB	Clinical Research Resources Branch, DAIDS
CTA	Clinical Trial Agreement
CWD	chronic wasting disease
DAIDS	Division of Acquired Immunodeficiency Syndrome
DAIT	Division of Allergy, Immunology, and Transplantation
DDCSB	Drug Development and Clinical Sciences Branch, DAIDS
DEA	Division of Extramural Activities
DHHS	Department of Health and Human Services
DIR	Division of Intramural Research
DIRB	DAIDS International Research Branch
DMID	Division of Microbiology and Infectious Diseases
DNA	deoxyribonucleic acid
DoD	Department of Defense
DSA	Drug Screening Agreements
EAMB	Extramural Administrative Management Branch, NIAID
EB	Epidemiology Branch, DAIDS
EHDB	Enteric and Hepatic Diseases Branch, DMID
EIR	Employee Invention Reports
ELISA	enzyme-linked immunosorbent assay
ELISPOT	enzyme-linked immunospot

ENSB	Extramural Network Systems Branch, NIAID
ESPRIT	Evaluation of Subcutaneous Proleukin in a Randomized International Trial
FCRDC	Frederick Cancer Research and Development Center
FDA	Food and Drug Administration
FOIA	Freedom of Information Act
FY	fiscal year
GBS	Group B streptococcus
GBV-B	GB virus type B
GBV-C	GB virus type C
GMB	Grants Management Branch, DEA
HAART	HIV highly active antiretroviral therapy
HBV	hepatitis B virus
HCV	hepatitis C virus
HHV	human herpesvirus
HIV	human immunodeficiency virus
HIVRAD	HIV Vaccine Research and Design Program
HIVRB	HIV Research Branch, DAIDS
HLA	human leukocyte antigen
HOPE	Health Omnibus Programs Extension of 1988
HPTN	HIV Prevention Trials Network
HSC	hematopoietic stem cell
HSV	herpes simplex virus
HUD	Department of Housing and Urban Development
HVAD	HIV Vaccine Awareness Day
HVCC	HIV Vaccine Communications Campaign
HVDDT	HIV Vaccine Design and Development Teams
HVTN	HIV Vaccine Trials Network
IAMB	Intramural Administrative Management Branch, NIAID
IAVI	International AIDS Vaccine Initiative
ICs	Institutes and Centers
ICAC	Inner-City Asthma Consortium
ICDs	Institutes, Centers, and Divisions
ICER	International Centers for Excellence in Research
ICIDR	International Collaboration in Infectious Disease Research
ICU	intensive care unit

IDPB	Infectious Disease Pathogenesis Branch, DIR
IHWG	International Histocompatibility Working Group
IL	interleukin
IND	investigational new drug
INRO	Intramural NIAID Research Opportunities
IOM	Institute of Medicine
IPCAVD	Integrated Preclinical/Clinical AIDS Vaccine Development Program
IPCP	Integrated Preclinical/Clinical Program
IPCP-HTM	Integrated Preclinical/Clinical Program for HIV Topical Microbicides
IRB	institutional review board
IRTA	Intramural Research and Training Awardees
ISAAC	International Studies of AIDS-Associated Co-Infections
ITN	Immune Tolerance Network
ITSB	Intramural Technical Systems Branch, NIAID
JDRF	Juvenile Diabetes Research Foundation International
LACD	Laboratory of Advanced Clinical Development, VRC
LAD	Laboratory of Allergic Diseases, DIR
LAM	Laboratory of Animal Medicine, VRC
LCID	Laboratory of Clinical Infectious Diseases, DIR
LCMI	Laboratory of Cellular and Molecular Immunology, DIR
LCT	Laboratory of Clinical Trials, VRC
LHBP	Laboratory of Human Bacterial Pathogenesis, DIR
LHD	Laboratory of Host Defenses, DIR
LI	Laboratory of Immunology
LICP	Laboratory of Intracellular Parasites, DIR
LID	Laboratory of Infectious Diseases, DIR
LIG	Laboratory of Immunogenetics, DIR
LIP	Laboratory of Immunopathology, DIR
LIR	Laboratory of Immunoregulation, DIR
LMI	Laboratory of Molecular Immunology, DIR
LMM	Laboratory of Molecular Microbiology, DIR
LMVR	Laboratory of Malaria and Vector Research, DIR
LPD	Laboratory of Parasitic Diseases, DIR
LPVD	Laboratory of Persistent Viral Diseases, DIR
LV	Laboratory of Virology, VRC
LVD	Laboratory of Viral Diseases, DIR

LVP	Laboratory of Vaccine Production, VRC
LVP	Laboratory of Viral Pathogenesis, VRC
<i>M.tb</i>	<i>Mycobacterium tuberculosis</i>
MACS	Multicenter AIDS Cohort Study
MADGC	Multiple Autoimmune Disease Genetics Consortium
M-CRADA	Materials Cooperative Research and Development Agreement
MDR-TB	multidrug-resistant tuberculosis
MERIT	Method to Extend Research in Time Award
MHC	major histocompatibility complex
MIRB	Microbiology and Immunology Review Branch, DEA
MISB	Management Information Systems Branch, NIAID
MMF	mycophenolate mofetil
MR4	Malaria Research and Reference Reagent Repository
MRI	magnetic resonance imaging
MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
MRU	Microbiology Research Unit
MS	multiple sclerosis
MSG	Mycoses Study Group
MSM	men who have sex with men
MTA	Material Transfer Agreement
MTCT	mother-to-child transmission
MVA	modified vaccinia Ankara
MVDB	Malaria Vaccine Development Branch, DIR
NAAIDC	National Advisory Allergy and Infectious Diseases Council
NARAC	North American Rheumatoid Arthritis Consortium
NARSA	The Network on Antimicrobial Resistance in <i>Staphylococcus aureus</i>
NBL	national biocontainment laboratory
NCRR	National Center for Research Resources
NHLBI	National Heart, Lung, and Blood Institute
NHPCSG	Nonhuman Primate Cooperative Study Group
NIAID	National Institute of Allergy and Infectious Diseases
NIALS	NIAID Immune Assessment Laboratory Service
NICHD	National Institute of Child Health and Human Development
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS	National Institute of Environmental and Health Sciences
NIGMS	National Institute of General Medical Sciences

NIH	National Institutes of Health
NK	natural killer [cells]
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRSA	National Research Service Award
NRTI	nucleoside reverse transcriptase inhibitor
NVP	nevirapine
NVPO	National Vaccine Program Office
OAS	Office of Administrative Services, NIAID
OCA	Office of Clinical Applications, DAIT
OCPL	Office of Communications and Public Liaison, NIAID
OCR	Office of Clinical Research, NIAID
OCRA	Office of Clinical Research Affairs, DMID
OD	Office of the Director, NIAID
OE	Office of Ethics, NIAID
OECT	Office of Epidemiology and Clinical Trials, DAIT
OFM	Office of Financial Management, NIAID
OGA	Office of Global Affairs
OHRM	Office of Human Resources Management, NIAID
OI	opportunistic infections
OKR	Office of Knowledge Resources
OMNI	Office of Management for New Initiatives, NIAID
ONR	Office of Naval Research
OPA	Office of Policy Analysis, NIAID
OPCO	Office of Program Coordination and Operations, DEA
OPCRO	Office for Policy in Clinical Research Operations, DAIDS
OPOSI	Office of Program Operations and Scientific Information, DAIDS
OPOSI	Office of Program Planning, Operations, and Scientific Information, DAIT
ORA	Office of Regulatory Affairs, DMID
OSCPO	Office of Scientific Coordination and Program Operations, DMID
OSPRT	Office of Special Populations and Research Training, NIAID
OSRD	Office of Scientific Resource Development
OTD	Office of Technology Development, NIAID
OTIS	Office of Technology Information Systems, NIAID
OTSEP	Office of Training and Special Emphasis Programs
OTT	Office of Technology Transfer, NIH
PA	program announcement

PAB	Pharmaceutical Affairs Branch, DAIDS
PACTG	Pediatric AIDS Clinical Trial Group
PATH	Program for Appropriate Technology in Health
PAVE	Partnership for HIV/AIDS Vaccine Evaluation
PBRB	Pathogenesis and Basic Research Branch, DAIDS
PEG-IFN	pegylated-interferon
PEPFAR	President's Emergency Plan for HIV/AIDS Relief
PFGRC	Pathogen Functional Genomics Resource Center
PGL	phenolic glycolipid
PID	primary immunodeficiency diseases
PIDR	Primary Immunodeficiency Diseases Registry
PIPB	Parasitology and International Programs Branch, DMID
PMB	Pediatric Medicine Branch, DAIDS
PR	protease
PRDB	Preclinical Research and Development Branch, DAIDS
PRP	polyribosylribose phosphate
PrP	prion protein
PSB	Prevention Sciences Branch, DAIDS
RAB	Regulatory Affairs Branch, DAIDS
RBL	Regional Biocontainment Laboratories
RCE	Research Centers of Excellence
RCMI	Research Centers in Minority Institutions
R&D	research and development
RDB	Respiratory Diseases Branch, DMID
RFA	request for applications
RFP	request for proposals
RML	Rocky Mountain Laboratories
RMVB	Rocky Mountain Veterinary Branch, DIR
RNA	ribonucleic acid
RPAB	Referral and Program Analysis Branch, DEA
RSUM	Research Supplements for Underrepresented Minorities
RSV	respiratory syncytial virus
RT	reverse transcriptase
RTB	Research Technologies Branch, DIR
SARS	severe acute respiratory syndrome
SARS-CoV	SARS-associated coronavirus

SBIR	Small Business Innovation Research
SLE	systemic lupus erythematosus
SMART	Strategies for Management of Anti-Retroviral Therapy
SNP	single nucleotide polymorphism
SPR	Summer Policy Retreat
SRB	Special Review Branch, DEA
SRP	Scientific Review Program, DEA
STD	sexually transmitted diseases
STI	sexually transmitted infections
STIB	Sexually Transmitted Infections Branch, DMID
STI CTG	Sexually Transmitted Infections Clinical Trials Group
STTR	Small Business Technology Transfer
TAACF	Tuberculosis Antimicrobial Acquisition and Coordinating Facility
TB	tuberculosis
TBRU	Tuberculosis Research Unit
TDRU	Tropical Diseases Research Unit
TEAC	Technology Evaluation Advisory Committee
TIB	Targeted Interventions Branch, DAIDS
TIB	Transplantation Immunobiology Branch, DAIT
TIGR	The Institute for Genomic Research
TMP-SMX	trimethoprim-sulfamethoxazole
TMRC	Tropical Medicine Research Centers
TRP	Therapeutics Research Program, DAIDS
TSE	transmissible spongiform encephalopathy
USAID	U.S. Agency for International Development
USAMRIID	U.S. Army Medical Research Institute of Infectious Diseases
USAMRMC	U.S. Army Medical Research and Materiel Command
USIDNET	U.S. Immunodeficiency Network
USJCMSP	U.S.–Japan Cooperative Medical Science Program
VA	Veterans Administration
VB	Virology Branch, DMID
VCRB	Vaccine Clinical Research Branch, DAIDS
VDRG	Vaccine Developmental Resources Group
Vif	Virion Infectivity Factor
VPP	Vaccine Pilot Plant

VPRP	Vaccine and Prevention Research Program, DAIDS
VRC	Vaccine Research Center
VRE	vancomycin-resistant enterococci
VZV	varicella-zoster virus
WG	Wegener's granulomatosis
WHO	World Health Organization
WIHS	Women's Interagency HIV Study
WITS	Women and Infants Transmission Study
WNV	West Nile virus
WPR	Winter Program Review

INDEX

A

Academic Research Enhancement Award (AREA) 179, 182

Acambis, Inc. 77

Acquired Immunodeficiency Syndrome (AIDS) i-iii, v, 5-7, 9, 11-16, 24, 26, 28, 30-31, 33, 35-36, 38-44, 46, 64-66, 72, 75, 78, 90-93, 95, 104-108, 111-112, 114, 116, 119, 121, 123, 126-128, 134-136, 141, 143-146, 148-153, 164-165, 167, 170, 182

Acquired Immunodeficiency Syndrome Research Review Committee 148

Acquisition Management and Operations Branch (AMOB), NIAID 182, 201

Acute HIV Infection and Early Disease Research Program (AIEDRP) 91, 182

Adenoviral Vectors (ADV) 34, 36, 59, 175, 182

Adult AIDS Clinical Trials Group (AACTG) 12, 16, 35, 42, 66, 106-107, 134, 182

Aedes aegypti 85, 89

agreements 4, 37, 78, 80, 92, 145, 148, 156, 171

AIDS. *See* acquired immunodeficiency syndrome

AIDS Clinical and Epidemiology Research Review Branch (ACERRB), DEA 182, 205

AIDS Preclinical Research Review Branch (APRRB), DEA 182, 205

AIDS Research Advisory Committee 14, 38, 128, 150

AIDS Research and Reference Reagent Program 12, 16, 75, 95, 136

AIDS Vaccine Research Working Group (AVRWG) 14, 128, 152, 182

Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) 164, 182

allergen immunotherapy (AIT) 51

allergy ii, 5, 26-27, 49-51, 98, 112, 141, 154

Allergy, Immunology, and Transplantation Research Committee 154

Alliance for Cellular Signaling (AfCS) 62, 182

Animal (Mammalian and Nonmammalian) Model and Animal and Biomedical Materials Resource Cooperative Agreements 181

anthrax 9, 22, 54, 56, 58-60, 71-73, 83-84, 89-90, 136, 173

Antimicrobial Drug Resistance 23, 141

antiretroviral therapy (ART) 12-13, 39, 41, 43, 64-65, 91, 105-106, 119, 141, 182

antiviral agents 67, 81, 139

arbovirus 139

arthritis i-ii, 18, 53, 64, 69, 86, 88, 98, 137, 171

Arthritis Foundation 53, 88, 137

ASIR. *See* Richard M. Asofsky Scholars in Research

Aspergillus fumigatus 83, 85, 89, 182

Associate Director for Management and Operations (ADMO) 160, 182, 201

asthma i-iii, 17-18, 26-27, 49-51, 69-70, 86-87, 97, 103-104, 141-142

Asthma and Allergic Diseases Research Centers (AADRC) 17, 20, 50

atopic dermatitis 51, 54

autoimmune diseases iii, 9, 17-18, 27, 52-53, 69-70, 87-88, 97, 103-104, 120, 124, 133, 137

Autoimmune Diseases Coordinating Committee (ADCC) 52, 104, 182

Autoimmunity Centers of Excellence (ACE) 18, 20, 52, 69, 88, 99, 104, 182

Aviron 80, 175

awards v, 10, 19, 26, 37-38, 42, 56-57, 73, 88, 91-92, 101, 108, 112, 116, 145, 168, 171, 179-180

azithromycin 68, 109

B

bacterial vaginosis 114

bacteriology 21, 156

Bacteriology and Mycology Biostatistical and Operations Unit (BAMBU) 68, 182

Bacteriology and Mycology Branch (BMB), DMID 182

Bacteriology and Mycology Study Group (BAMSG) 46, 68, 91, 182

Basic Immunology Branch (BIB), DAIT 182, 204

Basic Sciences Program (BSP), DAIDS 11, 182, 202

bilateral programs 92

Biodefense and Emerging Infections Research Resources Program 72

Biodefense Research Agenda for CDC Category A Agents i, 9

biodiversity 93

bioengineering 61

biofilms 47

bioinformatics 4, 22, 31, 56-57, 61, 63, 86-87, 140

- Bioinformatics Integration Support Contract (BISC) 63, 182
- Biology of the Microbe 58
- Biomedical Research After School Scholars (BRASS) 6, 182
- biosafety level (BSL) 27, 72, 182
- Biotechnology Engagement Program 93
- Board of Scientific Counselors (BSC), NIAID 29, 38, 158, 182
- borreliosis 73, 78-79
- bovine spongiform encephalopathy or "mad cow" disease (BSE) 26, 81, 182
- breastfeeding 14, 41, 106
- Brucella suis* 55, 84
- Brugia malayi* 89
- bubonic plague 58, 141
- budget iii, 3-4, 8, 10, 37-38, 92, 158, 164-165, 172
- BufferGel® 116-117
- Burkholderia mallei* 55, 58, 74, 84-85, 89
- Burkholderia pseudomallei* 58, 74, 85, 89
- Burkholderia thailandensis* 89
- C**
- canarypox 127
- capsid 40
- carcinogenesis 92
- Career Development Award 177
- Career Transition Award 177
- Category A, B, and C agents 22, 55, 72, 85
- CD25 174
- CD4+ T cells 43-44
- Center Core Grant 178
- Centers for AIDS Research (CFAR) 12, 16, 92, 108, 183
- Centers for Disease Control and Prevention (CDC) i, 9, 15, 41, 47, 52, 54, 67, 73-74, 76, 78, 80, 104, 111, 121, 128, 130-131, 134, 141-143, 147, 151, 153, 164, 183
- Center for HIV/AIDS Vaccine Immunology (CHAVI) 128, 183
- Chagas disease 89
- chlamydia 24, 62, 83, 108, 114-115, 126, 129
- chronic fatigue syndrome 170
- chronic wasting disease (CWD) 26, 81-82, 183
- cidofovir 57
- CIPRA. *See* Comprehensive International Program of Research on AIDS
- Civilian Research and Development Foundation 93
- Clinical Immunology Branch (CIB), DAIT 183, 204
- Clinical Investigator Award 177
- Clinical Research Curriculum Award (CRCA) 178, 183
- Clinical Research Management Branch (CRMB), DAIDS 183, 203
- Clinical Research Resources Branch (CRRB), DAIDS 183, 203
- clinical studies 12, 80
- clinical trials 6-7, 12-14, 18-19, 21-23, 30-36, 42-43, 52-53, 59, 66, 68-69, 77, 80, 87-88, 91, 98, 100-101, 103-104, 106-107, 111, 114-118, 121-123, 127-130, 132, 134-135
- Clinical Trial Agreement (CTA) 172, 183
- Clostridium botulinum* 73, 85
- Clostridium perfringens* 55, 74, 84, 89
- Coccidioides immitis* 73, 89
- Collaborative Antiviral Study Group (CASG) 46, 57, 68, 76, 182
- Committee Management Office 38
- community-acquired pneumonia (CAP) 47, 67-68, 182
- Community Advisory Board (CAB) 15, 182
- Community Education and Outreach Partnership Program (CEOPP) 7, 108, 183
- Community Programs for Clinical Research on AIDS 12, 16, 42, 66, 107, 170, 183
- Comparative Medicine Branch (CMB) 183, 205
- Complications and Co-Infections Research Branch (CCRB), DAIDS 182, 203
- Comprehensive International Program of Research on AIDS (CIPRA) 14, 42, 92, 123, 183
- computer linkages 27
- Conference Grant 179
- Confidential Disclosure Agreements (CDA) 172, 183
- Contract Management Program (CMP) 37, 183
- Cooperative Agreement 180-181
- Cooperative Centers for Translational Research on Human Immunology and Biodefense 20, 55, 132
- Cooperative Clinical Trials in Pediatric Transplantation (CCTPT) 118, 183
- Cooperative Research and Development Agreement (CRADA) 4, 34, 70, 80, 135, 172-173, 183, 186

Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense 56

coronavirus 34, 67, 71, 74-77, 85, 135, 139, 142, 189

Coxiella burnetii 55, 74, 84

CPCRA. *See* Terry Beirn Community Programs for Clinical Research on AIDS

Creutzfeldt-Jakob disease (CJD) 81, 183

Crohn's disease 70, 142, 175

Crucell 174

Cryptococcus neoformans 83, 89

Cryptosporidium parvum 55, 66, 74, 83-84, 89

Culex pipens 89

cytokine 33, 70, 86, 174

cytomegalovirus (CMV) 21, 33, 67, 126, 129, 139, 183

cytotoxic T lymphocytes 14, 40

D

Dale and Betty Bumpers Vaccine Research Center (VRC) 6, 30-36, 59, 90-91, 112, 126, 128, 134-135, 165, 173, 185-186, 190, 193, 199, 202, 206-207

databases 24-25, 56, 62-64, 66, 83, 85-87, 100

dengue i, 28, 33, 71-72, 77, 126, 133, 139

deoxyribonucleic acid (DNA) 24, 26, 33-35, 40, 44, 47, 50, 55, 59, 64, 70, 75, 77, 83, 87, 91, 124, 127, 130-131, 134-137, 140, 173-176, 183

Department of Defense (DoD) 15, 22, 41, 54, 62, 128, 183

Department of Energy 84

Department of Health and Human Services (DHHS) 1, 3-4, 8, 22, 92-93, 122, 126, 147, 163-164, 170, 181, 183

diabetes i, iii, 52-53, 64, 69, 86-87, 98, 118, 164

diagnostic tools 21, 67-68, 72, 125

diarrheal diseases 46

directors 15, 29, 52, 94, 128, 148, 163, 171

Division of Acquired Immunodeficiency Syndrome (DAIDS), NIAID 11, 37, 64-69, 91, 107, 115, 122-123, 126-129, 134, 136, 150, 161, 183, 202-203

Division of Allergy, Immunology, and Transplantation (DAIT), NIAID 17-18, 37, 49, 52-53, 63, 68-69, 86-87, 97-99, 118-120, 123-124, 126, 131-132, 137, 161, 176, 182-183, 187, 189, 203

Division of Computer Research and Technology 27

Division of Extramural Activities (DEA), NIAID 37, 182-184, 186-189, 204

Division of Intramural Research (DIR), NIAID 26-29, 31, 43, 47-48, 58-60, 70, 75, 81, 90, 95, 100, 112-113, 124-126, 133-134, 137, 158-160, 173, 175, 183, 185-186, 188, 205

Division of Microbiology and Infectious Diseases (DMID), NIAID 21-25, 30-31, 34, 36-37, 66-68, 77, 81, 83, 115-116, 121-122, 126, 129-131, 133, 138, 160-161, 175-176, 182-183, 187-189, 204

DNA. *See* deoxyribonucleic acid

DnaE2 141

Drug Development and Clinical Sciences Branch (DDCSB), DAIDS 183, 203

drug discovery 12, 21, 27, 44, 64-67, 123-124

drug resistance 21, 23, 28, 42-43, 45-47, 65, 78, 95, 100, 124, 141

Drug Screening Agreements (DSA) 172, 183

E

E25 anti-IgE 176

ebola virus 174

Education Project 179

Ehrlichia spp 89

Ehrlichiosis 73, 79, 89

emerging and re-emerging infectious diseases 22, 74

Emerging Viral Diseases Centers 77

Employee Invention Reports (EIR) 172, 183

end-stage renal disease 118

Entamoeba histolytica 55, 74, 83-84, 89

enteric 55, 73, 92, 141, 183

enterococci 45, 141, 190

Environmental Protection Agency 50

enzyme-linked immunosorbent assay (ELISA) 79, 184

enzyme-linked immunospot (ELISPOT) 87, 98, 184

Escherichia coli 55, 84, 89

Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) 42, 184

Expert Panel on Atopic Dermatitis and Vaccinia Immunization 54

Expert Panel on Immunity and Biodefense 54

Exploratory and Developmental Grants 179

Exploratory Grants Cooperative Agreements 181

F

Fauci, Anthony S. iii, v, 145, 160

filariasis 138

fiscal year (FY) 10, 14, 18-19, 46, 50-52, 56-57, 66-69, 72, 75, 77, 79, 85-86, 88-93, 99, 103, 108-113, 115, 118-119, 122, 128, 132, 137, 163-168, 171-174, 184

flaviviruses 28, 77

FluMist 23, 80, 133

Fogarty International Center 1, 4, 126

food allergy 49

Food and Drug Administration (FDA) 1, 23, 34, 36, 47, 52, 66-67, 72, 75, 80, 121-122, 130, 153, 184

Francisella tularensis 73, 85, 89

Frederick Cancer Research and Development Center (FCRDC) 27, 184

Freedom of Information Act (FOIA) 4, 184

G

gas gangrene 89

genomics 20, 23-24, 56, 76, 83, 85-86, 110, 119, 122, 140, 188

Giardia lamblia 55, 74, 84, 89

GlaxoSmithKline 24, 68, 109, 115, 124, 175

Global Alliance for Vaccines and Immunization 93, 130

global health v, 9, 22-24, 67, 71-72, 78, 90, 138, 152

Global Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis 9, 71, 78, 90

glycoprotein 34, 135

gonorrhea 23-24, 83, 108, 114, 129

gp120 32-34

graft rejection 19, 70, 86-88, 104, 110, 118-119

grants iii, 11, 13, 22-24, 37-39, 46, 56, 65, 68-69, 72, 75, 78-80, 92, 99, 112, 114, 121, 123, 126, 145, 148, 154, 156, 171, 178-180

Grants Management Branch (GMB) 37, 184, 205

Group B Streptococcus (GBS) 89, 109, 184

H

HAART. *See* highly active antiretroviral therapy

health disparities 9, 103, 108, 143

Health Omnibus Programs Extension (HOPE) 150, 170, 184

hematopoietic stem cell 53, 104, 110, 120, 184

hemorrhagic fevers 67, 73, 139

hepatitis A ii, 74

hepatitis B virus (HBV) 43, 184

Hepatitis C Cooperative Research Centers 95, 104

hepatitis C virus (HCV) 9, 42-43, 73, 94-96, 104, 142-143, 175, 184

hepatitis E virus 73, 133

herpes simplex virus (HSV) 109, 173, 184

Herpevac Trial for Women 109, 115

highly active antiretroviral therapy (HAART) 12, 39, 42-44, 64, 105-106, 119, 184

histocompatibility 61, 88, 110, 120, 124, 132, 137, 186

Histoplasma capsulatum 89

HIV/AIDS ii-iii, 6-7, 9, 11, 13-15, 24, 30, 39-42, 44, 64-65, 72, 78, 90-92, 104-105, 107-108, 114, 123, 127-128, 135, 143, 164-165, 183, 188

HIV Prevention Trials Network (HPTN) 14, 16, 41, 91, 106, 116-117, 184

HIV Vaccine Design and Development Teams (HVDDT) 14, 16, 127, 184

HIV Vaccine Developmental Resources Contracts 16

HIV Vaccine Research and Design Program (HIVRAD) 13, 16, 127, 184

HIV Vaccine Trials Network (HVTN) 6, 13, 16, 35, 41, 91, 106, 127-129, 134, 136, 152, 184

human immunodeficiency virus (HIV) i, 9, 11, 39, 184

human leukocyte antigen (HLA) 14, 53, 88, 110, 120, 124, 132, 184

human papillomavirus 105-106

Human Resources Operations Branch C 4

I

immune-based therapies 18, 50, 57, 69, 87

immune response ii, 12-13, 24, 27-28, 31-33, 35-36, 51, 53, 55, 58-59, 61-62, 74-75, 80, 86, 88, 95, 119-120, 124, 130-131, 133-134, 173

immune system i-ii, 11-13, 17-19, 26-27, 30, 32-33, 39-40, 42-43, 47, 50, 52, 54, 61, 64-65, 69-71, 86-88, 97-98, 103, 118-120, 123-124, 126, 128, 132, 141

immune tolerance 53, 69, 86-87, 97-99, 118-119

Immune Tolerance Network (ITN) iii, 18, 20, 50, 52, 69, 85, 87, 89, 97, 104, 119, 185

immunogenetics 87, 154

immunomodulation trials 20, 132

immunostimulants 56

immunotherapy 51, 75, 98, 182

Independent Scientist Award 177

infectious diseases i, iii, v, 9, 21-22, 24-28, 45, 54-57, 63-64, 66, 68, 70-73, 83-85, 90-93, 112, 120, 124, 126, 130-132, 137, 140, 145, 156, 181

- influenza i-ii, 6, 21-23, 28, 64, 67, 71-75, 79-81, 85, 89, 129-131, 133, 139, 142
- influenza viruses 79-80
- Inner-City Asthma Consortium (ICAC) 18, 20, 50, 184
- Inner-City Asthma Study iii, 49, 50, 103
- innovation grants 13
- Innovation Grants for AIDS Research Program 11, 44, 65, 116
- Institutes, Centers, and Divisions (ICDs) 29, 164, 184
- Institutes and Centers (ICs) 52, 90, 94, 120, 164, 167, 184
- Institute of Medicine (IOM) 8, 129, 185
- Institutional NRSA 180
- insulin 65, 86, 98
- Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Program 13, 16, 127, 185
- Integrated Preclinical/Clinical Program (IPCP) 12, 16, 44, 65, 116, 185
- Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP-HTM) 116, 185
- intensive care units 45
- Interagency Task Force on Antimicrobial Resistance 47
- interferon 43, 76, 94, 104, 139, 188
- interleukin-2 44, 141
- interleukin-4 86
- international agencies and organizations 93
- International Centers for Excellence in Research (ICER) 90, 184
- International Centers for Infectious Diseases Research 68
- International Centers for Tropical Diseases Research 102
- International Collaboration in Infectious Disease Research (ICIDR) 91, 185
- International Cooperative Biodiversity Groups Program 93
- International Histocompatibility Working Group (IHWG) 53, 88, 120, 185
- International Studies of AIDS-Associated Co-Infections Program (ISAAC) 44, 65, 186
- International Studies of AIDS-Associated Co-infections Program (INRO) 123, 185
- Intramural NIAID Research Opportunities 112, 185
- Intramural NRSA Individual Postdoctoral Program 177
- Intramural Research and Training Awardees (IRTA) 112-113, 185
- Intramural Research Programs 58
- Intramural Research Training and Collaborative Research 90
- investigational new drug (IND) 34, 185
- Ixodes scapularis* 85, 89
- ## J
- Japan 90, 92, 102, 189
- Japanese encephalitis virus 60, 74
- Jordan Report 23
- Juvenile Diabetes Research Foundation International (JDRF) 50, 52, 69, 87, 97, 104, 119, 185
- ## K
- kidney iii, 19, 62, 69, 87, 98, 110, 118-119, 143
- Kyasanur forest virus 74
- ## L
- laboratories 5, 26-27, 53, 57-58, 70, 81, 88, 90, 98, 100, 102-103, 112, 120, 130, 139, 158, 172, 188
- Laboratory of Advanced Clinical Development (LACD), VRC 182, 202
- Laboratory of Allergic Diseases (LAD), DIR 2, 185, 205
- Laboratory of Animal Medicine (LAM), VRC 2, 185, 202
- Laboratory of Cellular and Molecular Immunology (LCMI), DIR 2, 185, 205
- Laboratory of Clinical Infectious Diseases (LCID), DIR 2, 185, 205
- Laboratory of Clinical Trials (LCT), VRC 2, 185, 202
- Laboratory of Host Defenses (LHD), DIR 2, 173, 175, 185, 205
- Laboratory of Human Bacterial Pathogenesis (LHBP), DIR 2, 185, 205
- Laboratory of Immunogenetics (LIG), DIR 2, 174-175, 185, 205
- Laboratory of Immunology (LI) 2, 174, 202, 205
- Laboratory of Immunopathology (LIP), DIR 2, 185, 206
- Laboratory of Immunoregulation (LIR), DIR 2, 174, 185, 206
- Laboratory of Infectious Diseases (LID), DIR 2, 173-174, 185, 206

- Laboratory of Intracellular Parasites (LICP), DIR 2, 174, 185, 206
- Laboratory of Malaria and Vector Research (LMVR), DIR 185, 206
- Laboratory of Molecular Immunology (LMI), DIR 185, 206
- Laboratory of Molecular Microbiology (LMM), DIR 2, 176, 185, 206
- Laboratory of Parasitic Diseases 2, 185, 195, 206
- Laboratory of Persistent Viral Diseases (LPVD), DIR 2, 206
- Laboratory of Vaccine Production (LVP), VRC 2, 202
- Laboratory of Viral Diseases (LVD), DIR 2, 173, 176, 206
- Laboratory of Viral Pathogenesis (LVP), VRC 2, 151, 202
- Laboratory of Virology (LV), VRC 2, 202
- Laboratory Review Process, DIR 28-29
- lactobacillus 176
- Large-Scale Antibody and T Cell Epitope Discovery Program 133
- Lassa virus 9, 36, 59, 135
- La Montagne, John R. v
- Legionella pneumophila* 89
- Legionnaire's disease 89
- legislative chronology 170
- leishmaniasis 89
- Leishmania major* 89
- leprosy 93, 138
- licensure 23, 35, 36, 72, 114
- Liver and Pancreatic Disease in HIV Infection Program 44, 65-66
- Lyme Disease 5, 78, 89
- M**
- M.tb* 66, 72, 78, 111, 121-124, 138, 186
- "mad cow" disease. *See* bovine spongiform encephalopathy
- magnetic resonance imaging (MRI) 62, 186
- major histocompatibility complex (MHC) 61, 63, 124, 132, 137, 186
- malaria i-ii, 21, 23-24, 26, 28, 45-46, 62, 65-67, 71, 83-85, 89-91, 100-102, 111, 121, 124, 126, 129, 132, 134, 138, 141, 164
- Malaria Research and Reference Reagent Resource (MR4) 85, 101
- Malaria Research and Training Center 27
- Malaria Vaccine Development Branch (MVDB) 100, 133, 186, 206
- malignancies 64-66, 105, 119
- Marburg virus 9
- mast cells 27, 86
- Materials Cooperative Research and Development Agreement (M-CRADA) 172, 186
- Material Transfer Agreement (MTA) 172, 186
- Maxygen 175
- men who have sex with men (MSM) 6-7, 41-42, 105, 107-108, 115, 186
- Mentored Patient-Oriented Research Career Development Award 177
- Mentored Quantitative Research Career Development Award 177
- merozoite surface protein 176
- methicillin-resistant *Staphylococcus aureus* (MRSA) 45, 141, 186
- Method to Extend Research in Time (MERIT) Award 179-180, 186
- MHC tetramer core facility 137
- microbes i-ii, 9, 21-26, 54-56, 61, 83, 109, 114, 140
- microbicides 11, 14, 42, 68, 106, 109-110, 114-117
- Microbiology and Infectious Diseases Research Committee 156-157
- Microbiology Research Unit (MRU) 186
- Microchip drug delivery system 62
- Midcareer Investigator Award in Patient-Oriented Research 177
- minority health 1, 103
- Minority Researchers' Training Program 111
- modified vaccinia Ankara (MVA) 36, 40, 56, 58-59, 127, 134, 142, 186
- monkeypox 22, 59, 71, 142
- mother-to-child transmission (MTCT) ii, 13-14, 41-43, 106, 186
- Multicenter AIDS Cohort Study (MACS) 11, 16, 39, 105, 136, 186
- Multidrug-resistant tuberculosis (MDR-TB) 46, 58, 74, 186
- Multilateral Initiative on Malaria v, 93, 102, 130, 138
- Multiple Autoimmune Disease Genetics Consortium (MADGC) 53, 88, 137, 186
- multiple sclerosis (MS) iii, 53, 64, 69, 98, 104, 186
- musculoskeletal and skin diseases 53, 88, 137, 171
- Mycobacterium smegmatis* 85, 89, 122
- Mycobacterium tuberculosis* (*M.tb*). *See M.tb*

Mycology 21, 46, 68, 91, 156, 182
 mycophenolate mofetil (MMF) 70, 186
 Mycoses Study Group (MSG) 68, 186

N

National Academy of Sciences 26, 129
 National Advisory Allergy and Infectious Diseases Council (NAAIDC), NIAID 8, 29, 37, 92, 145, 158, 186
 National Biocontainment Laboratory (NBL) 22, 72, 186
 National Cancer Institute 1, 62, 66, 124, 133
 National Center for Research Resources (NCRR) 108, 164, 181, 186
 National Center on Minority Health and Health Disparities 1
 National Heart, Lung, and Blood Institute (NHLBI) iii, 1, 50, 69, 118, 186
 National Institute of Allergy and Infectious Diseases (NIAID) i-iii, v, 1-6, 8-10, 12-15, 18-19, 21-27, 29-31, 33, 34, 37-44, 46-59, 61-65, 67-68, 70-86, 88-97, 100-133, 136-141, 143-145, 147-150, 152, 154-160, 163, 165-168, 170-174, 177, 179, 181-187
 National Institute of Arthritis and Musculoskeletal and Skin Diseases 1, 53, 88, 137, 171
 National Institute of Child Health and Human Development (NICHD) 1, 14, 19, 88, 186
 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1, 50, 52, 63, 65-66, 69, 87, 95, 97-98, 104, 110, 118-119, 186
 National Institute of Environmental and Health Sciences (NIEHS) 1, 49-50, 131, 164, 187
 National Institute of General Medical Sciences (NIGMS) 1, 62, 86, 187
 National Institute on Drug Abuse 1, 14, 65
 National Institutes of Health (NIH) i, iii, v, 1, 3-6, 8, 12, 19, 22, 26-27, 29, 35-36, 38, 52-53, 56-57, 59, 63, 67, 70, 72, 75, 79, 81-82, 90, 92, 94-95, 100, 103-104, 111, 113, 120-121, 128, 134, 136, 142-145, 147-149, 151-152, 154, 156-161, 163-165, 167-168, 170-173, 177-181, 187-188
 National Research Service Award (NRSA) 177, 180, 187
 National Vaccine Program Office (NVPO) 130, 187
 natural killer (NK) cells 44, 187
Nematode species 89
 Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) 46, 140, 186

neurosyphilis 114
 neutrophil 58
 nevirapine (NVP) 43, 106, 187
 new drugs and therapeutic agents 12
 North American Rheumatoid Arthritis Consortium (NARAC) 53, 88, 137, 186
 nosocomial infections 21, 45
 NRSA for Senior Fellows 177

O

Office of Administrative Services (OAS), NIAID 3, 160, 187, 201
 Office of Biodefense Research, NIAID 161
 Office of Clinical Research (OCR), NIAID 3, 160, 187, 201
 Office of Communications and Public Liaison (OCPL), NIAID 3, 5-6, 160, 187, 201
 Office of Ethics (OE), NIAID 3, 160, 187
 Office of Financial Management (OFM), NIAID 3, 161, 187, 201
 Office of Global Affairs (OGA), NIAID 4, 161, 187, 201
 Office of Human Resources Management (OHRM), NIAID 187, 201
 Office of Management for New Initiatives (OMNI), NIAID 4, 160, 187, 201
 Office of Naval Research (ONR) 84, 187
 Office of Policy Analysis (OPA), NIAID 4, 161, 187, 202
 Office of Special Populations and Research Training (OSPRT), NIAID 38, 103, 187, 205
 Office of Technology Development (OTD), NIAID 4, 161, 172-173, 187, 202
 Office of Technology Information Systems (OTIS) 4, 161, 187, 202
 Office of Technology Transfer (OTT), NIH 172, 188
 Office of the Director (OD), NIAID 3, 37, 160-161, 187, 201
 Office of Training and Special Emphasis Programs (OTSEP) 112, 187
 opportunistic infections (OI) 12, 39, 42, 64-65, 105, 108, 148, 187
 organ transplantation iii, 69, 118
 outreach activities 5, 14, 103, 106, 112

P

pancreatic disease 44, 65-66
 Pandemic Preparedness in Asia 75, 80
 parainfluenza 28, 67, 133, 139
 parasites ii, 21, 26, 28, 45-46, 62, 67, 83, 100, 138
 Partnership for HIV/AIDS Vaccine Evaluation (PAVE) 15, 41, 128, 188
 Pathogen Functional Genomics Resource Center (PFGRC) 56, 76, 85, 122, 140, 188
 pathogen genomics 24
 Pediatric AIDS Clinical Trials Group (PACTG) 12, 16, 66, 106-107
 pelvic inflammatory disease (PID) 24, 108
 pertussis vaccine v, 92
 PfEMP1 175
 plague 9, 26, 28, 56, 58, 83, 89, 141
 planning 3-4, 8-9, 14, 36, 38, 41, 72, 108, 117, 143-144, 181
Plasmodium falciparum 83, 100, 134, 144
Plasmodium vivax 89
 Pneumococcal Reference Laboratory 139
 pneumococcus 130
Pneumocystis carinii 66, 89
 pneumonia ii, 21, 23, 39, 45, 47, 66-68, 74, 79, 89, 130, 182
 policy retreats 8
 polymerase chain reaction (PCR) 59, 75
 polyribosylribose phosphate (PRP) 139, 188
 Postdoctoral Individual NRSA 177
 poxvirus 36, 58, 67, 134
 Predoctoral Individual National Research Service Award (NRSA) 177
 Prevention Research 11, 13, 41, 153
 Primary Immunodeficiency Diseases Registry (PIDR) 88, 137, 188
 primates 31, 33-34, 59, 81, 116, 129, 134
 prion diseases 26, 28, 73, 81
 prion protein (PrP) 81, 188
 PRO 2000/5 gel 116-117
Profile iii
 program announcement (PA) 63, 107, 176, 188
 program reviews 8
 Project EXPLORE 41-42
 protease (PR) 13, 42, 64, 94, 188
 protease inhibitors 13, 42

Protein Zinc Finger Domains 174
 proteins 11, 21, 24, 26, 32-34, 39, 55-56, 58-59, 61-65, 72, 74, 76, 81, 84, 86, 110, 123-124, 127, 132, 135, 140, 173-174
 proteomics 25, 58, 61
 Public Health Action Plan to Combat Antimicrobial Resistance 23, 47, 67

R

re-emerging diseases i, 22, 71
 Reagents and Reference Standards 139
 references 141
 Referral and Program Analysis Branch (RPAB), DEA 37, 188
 Regional Biocontainment Laboratories (RBL) 22, 72, 188
 repositories 123, 136, 138
 request for applications (RFA) 37, 92, 179, 188
 Research Agenda for Emerging Infectious Diseases 71
 research and development (R&D) ii, 4, 13, 15, 32, 36-37, 40, 63, 68, 72, 80, 95, 116, 126, 128, 130, 133, 166, 172-173, 178, 180-181, 188
 Research Centers in Minority Institutions (RCMI) 108, 188
 Research Centers of Excellence (RCE) 22, 72, 188
 Research Demonstration and Dissemination Project 179
 Research Program Project 178
 Research Project Grant 178
 Research Supplements for Underrepresented Minorities (RSUM) 108, 112, 188
 Resource-Related Research Project 179
 Resource-Related Research Projects/Cooperative Agreements 180
 respiratory syncytial virus (RSV) 28, 67, 129, 188
 reverse transcriptase (RT) 13, 42-43, 64, 187-188
 ribonucleic acid (RNA) 43-44, 64, 75, 188
 Richard M. Asofsky Scholars In Research (ASIR) 111-112, 182
Rickettsia rickettsii 89
Rickettsia typhi 55, 84, 89
 Rift Valley fever 73
 Rocky Mountain Laboratories (RML) 2, 5, 27, 79, 81-82, 205-206
 Rocky Mountain spotted fever 89

S

Salmonella 46, 55, 74, 84-85, 89, 141
Salmonella typhi 89
 SARS. *See* severe acute respiratory syndrome
 SARS-associated coronavirus (SARS-CoV) 74-76, 189
Schistosoma mansoni 89
 schistosomiasis 70, 138-139, 142, 175
 Science Applications International Corporation 101
 Scientific Evaluation 179
 Scientific Review Program (SRP) 37, 189
 scleroderma 53, 103-104
 scrapie 81
 screening program 67, 139
 severe acute respiratory syndrome (SARS) i, 22-23, 28, 31, 34, 55-56, 60, 71, 73-77, 85, 129-130, 133, 135-136, 139, 142, 173-175, 189
 severe combined immunodeficiency disease 137
 sexually transmitted diseases (STDs) 9, 14, 41, 68, 110, 114, 143-144, 189
 sexually transmitted infections (STIs) 5, 21, 24, 42, 66, 68, 108-110, 114-115, 171, 189
 Shigella 46, 55, 74, 84-85
 Simian Vaccine Evaluation Units 16, 129, 136
 single nucleotide polymorphisms (SNP) 53, 120, 189
 Sjögren's syndrome 104
 skin diseases 1, 53, 88, 137, 171
 Small Business Biodefense Program 56
 Small Business Innovation Research (SBIR) 38, 65, 101, 115, 123, 180, 189
 Small Business Technology Transfer (STTR) 38, 180, 189
 small grant 179
 smallpox 9, 22, 28, 30-31, 36, 54-60, 67, 71, 73, 126, 132, 134-135, 142, 173
 specialized center 178
 St. Louis encephalitis virus 28
 Staphylococcus 23, 45-47, 55, 67, 73, 84-85, 140-141, 186
 STD Clinical Trials Unit 68, 109, 114-115
 STD Cooperative Research Centers 114
 STD Prevention Primate Unit 115
 strategic planning v, 8-9
 Strategic Plan for Addressing Health Disparities 9, 103

Strategies for Management of Anti-Retroviral Therapy (SMART) 42, 189
Streptococcus agalactiae 85, 89
Streptococcus pneumoniae 45, 85, 141
 structured intermittent therapy 43
 Summer Policy Retreat (SPR) 8, 10, 189
 Summit on Development of Infectious Disease Therapeutics 68
 syphilis 68, 108-109, 114-115, 129
 systemic lupus erythematosus (SLE) i, 52-53, 69, 86, 88, 103-104, 189

T

T cell 33-35, 44, 62-63, 76, 86-87, 98, 124, 133, 135, 137
 technologies i-ii, 4, 17, 25-26, 31, 33, 35, 38, 47, 56, 61-62, 68, 70, 83-86, 111, 122, 126, 130-132, 134, 138, 140, 172-173
 Technology Evaluation Advisory Committee (TEAC) 172, 189
 technology transfer 4, 57, 122, 129, 136, 138, 172
 Terry Beirn Community Programs for Clinical Research on AIDS 12, 16, 42, 66, 107, 170, 183
 Tetramer Core Facility 137
 Tetramer Facility 95, 124, 133
 The Institute for Genomic Research 85, 121, 189
 therapeutics ii, 12, 22-24, 28, 34, 42, 44, 54, 56-58, 65-66, 70, 72, 75-76, 78, 81, 84, 91, 100, 111, 122, 136, 140
 Therapeutics Research on AIDS-Associated Opportunistic Infections and Malignancies Program 44, 65
 thyroiditis 103
 topical microbicides 11, 14, 42, 68, 106, 109-110, 114-117
 Topical Microbicides Program 109, 110, 114
Toxoplasma gondii 55, 83-84, 89
 transmissible spongiform encephalopathy (TSE) 81-82, 189
 transplantation iii, 9, 17-19, 53, 69, 87, 98-99, 104, 110, 112, 118-120, 143-145, 154
Trichomonas vaginalis 89, 109
 trimethoprim-sulfamethoxazole (TMP-SMX) 46, 189
 tropical diseases 28, 90, 170
 Tropical Diseases Research Units (TDRU) 101, 189

Tropical Medicine Research Centers (TMRC) 24, 92, 189
Trypanosoma brucei 83, 89
Trypanosoma cruzi 85, 89
 trypanosomiasis 89
 tuberculosis (TB) i-ii, 9, 22-24, 28, 42, 46-47, 55, 58, 65-66, 71-72, 74, 78, 83, 86, 89-91, 93, 111, 121, 123-126, 129, 132, 134, 138, 141-144, 164-165, 171, 173, 175, 186, 189
 Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) 122, 144, 189
 Tuberculosis Research Unit (TBRU) 24, 46, 91, 111, 121-122, 189
 tularemia 9, 56, 73, 89
 typhoid fever 89

U

U.S. Agency for International Development (USAID) 93, 100, 121, 130, 134, 189
 U.S. Army Medical Research and Materiel Command (USAMRMC) 41, 128, 147, 189
 U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) 34, 58-59, 189
 U.S. Immunodeficiency Network (USIDNET) 20, 189
 U.S.-Japan Cooperative Medical Science Program (USJCMSP) 92, 102

V

Vaccine Action Program 102
 Vaccine and Treatment Evaluation Units 22, 46, 68, 101, 130
 vaccine candidates ii, 14, 31-36, 40, 56, 63, 80, 100-101, 111, 122, 125, 127, 129, 132, 134-135, 138, 173
 Vaccine Developmental Resources Group (VDRG) 129, 189
 Vaccine Pilot Plant (VPP) 32, 135, 190
 vaccine research and development ii, 13, 40, 126, 128, 130, 133
 vaccinia 36, 40, 51, 54-56, 58-60, 67, 127, 134, 139, 173-174, 186

vaginitis 89
 vancomycin-resistant enterococci (VRE) 45, 141, 190
 varicella-zoster virus (VZV) 67, 139, 190
Vibrio cholerae 46, 55, 84-85, 89
 viral hemorrhagic fevers 73, 139
 Virion Infectivity Factor (Vif) 39, 190
 viruses ii, 17, 21, 24, 26, 28, 30, 32-33, 56, 59, 61, 64, 67, 73-77, 80, 89, 132-133, 139
 VRC. *See* Dale and Betty Bumpers Vaccine Research Center

W

Walter Reed Army Institute of Research 101, 151, 153
 Warren Grant Magnuson Clinical Center 3, 26, 70
 Wegener's granulomatosis (WG) 70, 142, 190
 West Nile virus (WNV) i, 6, 22-23, 28, 30-31, 34, 36, 55, 59-60, 67-68, 71, 74, 76-77, 89, 129, 133, 135, 139, 173-174, 190
 Winter Program Review (WPR) 8, 10, 190
Wolbachia 89
 Women and Infants Transmission Study (WITS) 11, 16, 105, 136, 190
 women's health 38, 103
 Women's Interagency HIV Study (WIHS) 11, 16, 105-106, 136, 190
 World Health Organization (WHO) v, 74, 93, 102, 111, 121, 123, 130, 136, 139, 141, 190
 World Reference Center for Arboviruses 77

X

xenotransplantation 120

Y

yellow fever 77, 89, 139
Yersinia pestis 55, 58, 73, 84-85, 89